Qiagen (QGEN) Reports Q3 Results as EQT Nears €9.6 Billion Acqui
Qiagen (QGEN) reported Q3 net sales of $548M and adjusted EPS of $0.65, stable on a constant currency basis. EQT is in advanced talks to acquire Qiagen for approximately €9.6B. GuruFocus rates QGEN fairly valued with a GF Value of $50.01 and a GF Score of 75/100, indicating solid fundamentals.
How this was made
The 30-second read
Why it matters
The announcement immediately drove a price surge, reflecting market expectations of a takeover premium.
Market read
The deal represents a material M&A event for a mid‑cap biotech, likely moving the stock and influencing sector sentiment.
What to watch
Regulatory approval risk in the EU and potential antitrust scrutiny could delay or block the deal.
Background
Qiagen posted stable Q3 sales and earnings, and EQT's near‑final acquisition talks were announced on Oct 21 2026.
Ticker impact
Qiagen reported Q3 results and disclosed that private equity firm EQT is in advanced talks to acquire the company for approximately €9.6 billion.
upward pressure as the market anticipates a takeover premium
The deal size is material for a $10.3 bn market cap and the announcement caused an immediate price surge.
Market effects
Potential consolidation in the molecular diagnostics sector could spur M&A activity among peers.
European private‑equity activity may see increased interest in healthcare assets.
Large‑cap biotech M&A can influence broader market risk sentiment.
Counterpoint
If the acquisition falls through, the stock could retreat sharply from the current premium.
Key entities
- companyQiagen N.V.
Molecular diagnostics and life‑science solutions provider, ticker QGEN.
- private equity firmEQT
Potential acquirer offering €9.6 billion for Qiagen.
